Streetbeat News

Earnings

GRTX

NDRA

In Monday's pre-market session, several healthcare stocks showed significant movement. Galera Therapeutics (GRTX) led the gainers with a 62.8% increase, attributed to its Q4 earnings report. Other notable gainers include Sunshine Biopharma (SBFM), Qilian Intl Hldg Gr (QLI), Xilio Therapeutics (XLO), Innate Pharma (IPHA), and China Pharma Holdings (CPHI). On the losing side, ENDRA Life Sciences (NDRA) saw the largest drop of 29.3%, also following its Q4 earnings. Other decliners were SINTX Techs (SINT), Fractyl Health (GUTS), Vivos Therapeutics (VVOS), Avalo Therapeutics (AVTX), and Applied Therapeutics (APLT).

Portfolio Pulse from Benzinga Insights

April 01, 2024 | 12:08 pm

BCLI

BrainStorm Cell Therapeutics announced a fiscal year 2023 earnings per share (EPS) loss of $(0.40) and reported a cash balance of $1.45 million. This financial update could influence investor sentiment and stock performance in the short term.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 12:08 pm

CLSK

GDS

MIMO

SPEC

WRAP

XTKG

In Monday's pre-market session, several information technology stocks showed notable movements. Airspan Networks, Spectaire Holdings, and Wrap Technologies were among the top gainers, with Airspan leading at a 15% increase. On the downside, X3 Holdings, Cleanspark, and Movella Holdings experienced significant drops, with X3 Holdings leading the losses at 28.2%. Wrap Technologies and GDS Holdings also released their Q4 earnings recently, influencing their stock movements.

Portfolio Pulse from Benzinga Insights

April 01, 2024 | 12:07 pm

JAGX

Jaguar Health (NASDAQ:JAGX) reported Q4 sales of $2.30 million, missing the consensus estimate of $2.61 million by 11.88% and marking a 29.45% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 12:07 pm

NVAX

Novavax, Inc. (NASDAQ:NVAX) will present data on its updated COVID-19 vaccine and progress on its COVID-19-Influenza Combination vaccine at the World Vaccine Congress 2024. The updated vaccine shows robust neutralizing antibody titers against XBB.1.5 and JN.1 subvariants, with a safety profile consistent with its prototype. Novavax will also share differences in immune responses between mRNA and protein-based vaccines and discuss its influenza and combination vaccine candidates, including Phase 3 trial timelines.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 12:06 pm

SGRP

SPAR Group (NASDAQ:SGRP) reported a Q4 EPS of $0.11, up 37.5% from $0.08 YoY, with sales of $65.10M beating the $65.00M estimate, a 0.71% increase YoY.

Portfolio Pulse from dijoy@benzinga.com

April 01, 2024 | 12:05 pm

NNOX

Nano X Imaging (NNOX) reported Q4 adjusted EPS of $(0.18), surpassing the $(0.30) estimate, but its sales of $2.40M fell short of the $2.82M estimate. The EPS improved by 5.26% from last year, while sales saw a 12.43% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 12:04 pm

TLSI

TriSalus Life Sciences (NASDAQ:TLSI) reported Q4 2023 earnings with a GAAP EPS of $(1.56), missing the $(0.69) estimate by 126.09%. However, their sales of $5.721M exceeded the $5.453M estimate by 4.91%, marking a 77.34% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 12:02 pm

TCBI

Texas Capital Bancshares (NASDAQ:TCBI) has received mixed reviews from 10 analysts over the last three months, with ratings ranging from bullish to bearish. The average 12-month price target is now $66.00, down from $68.25, indicating a negative sentiment shift. Financial challenges such as a -11.16% revenue decline, below-average net margin, ROE, and ROA, along with a high debt-to-equity ratio, suggest operational and profitability hurdles. The company operates in major Texas metropolitan areas and specializes in secured lending.

Portfolio Pulse from Benzinga Insights

April 01, 2024 | 12:02 pm

SYPR

Sypris Solutions has revised its 2024 revenue growth forecast to 10%-15% year-over-year, down from the previously expected 15%-20%. Despite the adjustment, the company maintains a positive outlook due to strong backlog and new contract awards. Gross profit is anticipated to rise by 20%-25%, with gross margins expanding by 150-175 basis points.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 11:51 am